These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 25662055)

  • 1. Efficacy and survival in patients with cardiac contractility modulation: long-term single center experience in 81 patients.
    Kuschyk J; Roeger S; Schneider R; Streitner F; Stach K; Rudic B; Weiß C; Schimpf R; Papavasilliu T; Rousso B; Burkhoff D; Borggrefe M
    Int J Cardiol; 2015 Mar; 183():76-81. PubMed ID: 25662055
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes of plasma norepinephrine and serum N-terminal pro-brain natriuretic peptide after exercise training predict survival in patients with heart failure.
    Rengo G; Pagano G; Parisi V; Femminella GD; de Lucia C; Liccardo D; Cannavo A; Zincarelli C; Komici K; Paolillo S; Fusco F; Koch WJ; Perrone Filardi P; Ferrara N; Leosco D
    Int J Cardiol; 2014 Feb; 171(3):384-9. PubMed ID: 24388546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical, echocardiographic, and neurohormonal response to cardiac resynchronization therapy: are they interchangeable?
    Hoogslag GE; Höke U; Thijssen J; Auger D; Marsan NA; Wolterbeek R; Holman ER; Schalij MJ; Bax JJ; Verwey HF; Delgado V
    Pacing Clin Electrophysiol; 2013 Nov; 36(11):1391-401. PubMed ID: 23826659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac contractility modulation treatment in patients with symptomatic heart failure despite optimal medical therapy and cardiac resynchronization therapy (CRT).
    Kuschyk J; Nägele H; Heinz-Kuck K; Butter C; Lawo T; Wietholt D; Roeger S; Gutterman D; Burkhoff D; Rousso B; Borggrefe M
    Int J Cardiol; 2019 Feb; 277():173-177. PubMed ID: 30409733
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term results of intensified, N-terminal-pro-B-type natriuretic peptide-guided versus symptom-guided treatment in elderly patients with heart failure: five-year follow-up from TIME-CHF.
    Sanders-van Wijk S; Maeder MT; Nietlispach F; Rickli H; Estlinbaum W; Erne P; Rickenbacher P; Peter M; Pfisterer MP; Brunner-La Rocca HP;
    Circ Heart Fail; 2014 Jan; 7(1):131-9. PubMed ID: 24352403
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized comparison of 5 versus 12 hours per day of cardiac contractility modulation treatment for heart failure patients: A preliminary report.
    Kloppe A; Mijic D; Schiedat F; Bogossian H; Mügge A; Rousso B; Lemke B
    Cardiol J; 2016; 23(1):114-9. PubMed ID: 26503077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac contractility modulation: first experience in heart failure patients with reduced ejection fraction and permanent atrial fibrillation.
    Röger S; Schneider R; Rudic B; Liebe V; Stach K; Schimpf R; Borggrefe M; Kuschyk J
    Europace; 2014 Aug; 16(8):1205-9. PubMed ID: 24706089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of long-term survival by cardiac contractility modulation in heart failure patients: A case-control study.
    Liu M; Fang F; Luo XX; Shlomo BH; Burkhoff D; Chan JY; Chan CP; Cheung L; Rousso B; Gutterman D; Yu CM
    Int J Cardiol; 2016 Mar; 206():122-6. PubMed ID: 26788686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.
    de Antonio M; Lupon J; Galan A; Vila J; Urrutia A; Bayes-Genis A
    Am Heart J; 2012 May; 163(5):821-8. PubMed ID: 22607860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.
    von Haehling S; Jankowska EA; Morgenthaler NG; Vassanelli C; Zanolla L; Rozentryt P; Filippatos GS; Doehner W; Koehler F; Papassotiriou J; Kremastinos DT; Banasiak W; Struck J; Ponikowski P; Bergmann A; Anker SD
    J Am Coll Cardiol; 2007 Nov; 50(20):1973-80. PubMed ID: 17996563
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical effects of long-term cardiac contractility modulation (CCM) in subjects with heart failure caused by left ventricular systolic dysfunction.
    Müller D; Remppis A; Schauerte P; Schmidt-Schweda S; Burkhoff D; Rousso B; Gutterman D; Senges J; Hindricks G; Kuck KH
    Clin Res Cardiol; 2017 Nov; 106(11):893-904. PubMed ID: 28685207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness and predictive value of circulating NT-proBNP levels to stratify patients for referral and priority treatment in a specialized outpatient heart failure center.
    Amir O; Paz H; Ammar R; Yaniv N; Schliamser JE; Lewis BS
    Isr Med Assoc J; 2008 Feb; 10(2):109-12. PubMed ID: 18432021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy.
    Zile MR; Abraham WT; Weaver FA; Butter C; Ducharme A; Halbach M; Klug D; Lovett EG; Müller-Ehmsen J; Schafer JE; Senni M; Swarup V; Wachter R; Little WC
    Eur J Heart Fail; 2015 Oct; 17(10):1066-74. PubMed ID: 26011593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ADHF/NT-proBNP risk score to predict 1-year mortality in hospitalized patients with advanced decompensated heart failure.
    Scrutinio D; Ammirati E; Guida P; Passantino A; Raimondo R; Guida V; Sarzi Braga S; Canova P; Mastropasqua F; Frigerio M; Lagioia R; Oliva F
    J Heart Lung Transplant; 2014 Apr; 33(4):404-11. PubMed ID: 24485712
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First human chronic experience with cardiac contractility modulation by nonexcitatory electrical currents for treating systolic heart failure: mid-term safety and efficacy results from a multicenter study.
    Pappone C; Augello G; Rosanio S; Vicedomini G; Santinelli V; Romano M; Agricola E; Maggi F; Buchmayr G; Moretti G; Mika Y; Ben-Haim SA; Wolzt M; Stix G; Schmidinger H
    J Cardiovasc Electrophysiol; 2004 Apr; 15(4):418-27. PubMed ID: 15089990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization and prediction of natriuretic peptide "nonresponse" during heart failure management: results from the ProBNP Outpatient Tailored Chronic Heart Failure (PROTECT) and the NT-proBNP-Assisted Treatment to Lessen Serial Cardiac Readmissions and Death (BATTLESCARRED) study.
    Gaggin HK; Truong QA; Rehman SU; Mohammed AA; Bhardwaj A; Parks KA; Sullivan DA; Chen-Tournoux A; Moore SA; Richards AM; Troughton RW; Lainchbury JG; Weiner RB; Baggish AL; Semigran MJ; Januzzi JL
    Congest Heart Fail; 2013; 19(3):135-42. PubMed ID: 23279139
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjunctive therapy with low-molecular-weight heparin in patients with chronic heart failure secondary to dilated cardiomyopathy: one-year follow-up results of the randomized trial.
    Wojnicz R; Nowak J; Szyguła-Jurkiewicz B; Wilczek K; Lekston A; Trzeciak P; Nowalany-Kozielska E; Zembala M; Wodniecki J; Poloński L
    Am Heart J; 2006 Oct; 152(4):713.e1-7. PubMed ID: 16996844
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic value of N-terminal-pro-brain natriuretic peptide on admission in patients with chronic heart failure].
    Wang F; Li W; Huang J; Wang L; Bian WY; Pang HM; Wang Y; Xu ZM; Li YS
    Zhonghua Xin Xue Guan Bing Za Zhi; 2006 Jan; 34(1):28-32. PubMed ID: 16626545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intravenous iron reduces NT-pro-brain natriuretic peptide in anemic patients with chronic heart failure and renal insufficiency.
    Toblli JE; Lombraña A; Duarte P; Di Gennaro F
    J Am Coll Cardiol; 2007 Oct; 50(17):1657-65. PubMed ID: 17950147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term prognostic value and serial changes of plasma N-terminal prohormone B-type natriuretic peptide in patients undergoing transcatheter aortic valve implantation.
    Ribeiro HB; Urena M; Le Ven F; Nombela-Franco L; Allende R; Clavel MA; Dahou A; Côté M; Laflamme J; Laflamme L; DeLarochellière H; DeLarochellière R; Doyle D; Dumont E; Bergeron S; Pibarot P; Rodés-Cabau J
    Am J Cardiol; 2014 Mar; 113(5):851-9. PubMed ID: 24528616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.